DAEJEON, South Korea, Dec. 20, 2024 /PRNewswire/ -- Antimicrobial resistance (AMR) is a growing global health crisis because of microbes,…
JERSEY CITY, N.J., Dec. 18, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to…
Appointment of seasoned executives with substantial industry expertise strengthens team as the company advances programs into the clinicCAMBRIDGE, Mass., Dec.…
Milestone demonstrates the growing customer adoption of the Company’s proprietary technologyLEXINGTON, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems,…
- Xyngari (formerly DMT310) is currently being studied in Phase 3 for the treatment of acne, with topline results from…
LEXINGTON, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO), a leader in the rapid detection of sepsis-causing…
KNOXVILLE, Tenn., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today the…
- This is Dermata's first allowed U.S. patent application for DMT310, using its Spongilla technology to topically treat acne --…
Collaboration between Bascom Palmer Eye Institute and Provectus Biopharmaceuticals KNOXVILLE, TN / ACCESSWIRE / December 10, 2024 / VisiRose, a…
Intends to accelerate broad adoption of direct-from-whole-blood diagnostics, generate non-dilutive capital, and create a new royalty revenue streamLEXINGTON, Mass., Dec.…